News | February 16, 2024
Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
The talk show will be held monthly via Medanta's YouTube, Facebook and LinkedIn channe
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
The 200 bedded hospital owned & operated by Alexis
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
Additionally, an MoU was signed between the Dental Council of India and Quality Council of India for the assessment and rating of undergraduate dental colleges
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Subscribe To Our Newsletter & Stay Updated
